West Pharmaceutical Services (WST) Return on Capital Employed (2010 - 2026)

West Pharmaceutical Services has disclosed Return on Capital Employed across 17 years of filings, most recently posting 18.63% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 18.63%, up 78.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 18.63% (up 78.0% YoY), and the FY2025 annual result was 17.71%, down 17.0% from the prior year.
• Return on Capital Employed came in at 18.63% for Q1 2026 at West Pharmaceutical Services, up from 16.56% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 28.36% in Q2 2022 to a low of 16.56% in Q4 2025.
• The 5-year median for Return on Capital Employed is 20.29% (2023), against an average of 21.2%.
• Across the five-year window, Return on Capital Employed surged 653 bps in 2022 and sank 783 bps in 2023, its largest moves.
• West Pharmaceutical Services' Return on Capital Employed stood at 24.9% in 2022, then fell by 13 bps to 21.66% in 2023, then retreated by 15 bps to 18.33% in 2024, then decreased by 10 bps to 16.56% in 2025, then increased by 13 bps to 18.63% in 2026.
• The last three Return on Capital Employed figures came in at 18.63% (Q1 2026), 16.56% (Q4 2025), and 17.32% (Q3 2025), per Business Quant data.